Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia

Stephen A. Strickland(Vanderbilt University), Adam C. Seegmiller(Vanderbilt University Medical Center), Claudio A. Mosse(Breast Cancer Research Foundation), Aaron C. Shaver(Vanderbilt University), Robert Daber(University of Pennsylvania), Cindy L. Vnencak‐Jones(Vanderbilt University), P. Brent Ferrell(Vanderbilt University Medical Center), Michael R. Savona(Vanderbilt University), Sanjay Mohan(Breast Cancer Research Foundation), Tamara K. Moyo(Carolinas Medical Center), Thomas Stricker(Argonne National Laboratory), Michael Byrne(Vanderbilt University), David R. Head(University of Southern California)
Leukemia Research
January 2, 2018
10.1016/j.leukres.2017.12.012
Cited by 21

Related Papers

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Age and acute myeloid leukemia
|Blood|2006|1.4k
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
|Blood|1997|869
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.
|Journal of Clinical Oncology|1990|786